CDKN2A Primary Antibody
This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, MDM1, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene.
Ascitic fluid containing 0.03% sodium azide.
4°C; -20°C for long term storage
Figure 1: Western blot analysis using CDKN2A mAb against human CDKN2A recombinant protein. (Expected MW is 19 kDa)
Figure 2: Western blot analysis using CDKN2A mAb against HEK293 (1) and CDKN2A (AA: 1-156)-hIgGFc transfected HEK293 (2) cell lysate.
Figure 3: Flow cytometric analysis of HEK293 cells using CDKN2A mouse mAb (green) and negative control (red).
Figure 4: Immunohistochemical analysis of paraffin-embedded lung cancer tissues using CDKN2A mouse mAb with DAB staining.
Figure 5: Immunohistochemical analysis of paraffin-embedded endometrial cancer tissues using CDKN2A mouse mAb with DAB staining.
Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);
For Research Use Only. Not for use in diagnostic procedures.